{
    "Clinical Trial ID": "NCT00054275",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Docetaxel and OSI-774",
        "  docetaxel IV over 1 hour once weekly for 3 weeks and oral erlotinib once daily"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed stage IV or recurrent adenocarcinoma of the breast",
        "  Measurable disease",
        "  Disease recurrence must not be within 1 year of receiving prior adjuvant docetaxel",
        "  Stable brain metastases allowed",
        "  Hormone receptor status:",
        "  Not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Age",
        "  18 and over",
        "  Sex",
        "  Male or female",
        "  Menopausal status",
        "  Not specified",
        "  Performance status",
        "  ECOG (Eastern Cooperative Oncology Group) 0-2 OR",
        "  Karnofsky 60-100%",
        "  Life expectancy",
        "  More than 6 months",
        "  Hematopoietic",
        "  WBC(White Blood Count) at least 3,000/mm^3",
        "  Platelet count at least 100,000/mm^3",
        "  Absolute neutrophil count at least 1,500/mm^3",
        "  Hemoglobin at least 8 g/dL",
        "  Hepatic",
        "  Bilirubin normal",
        "  AST(aspartate aminotransferase)/ALT(alanine aminotransferase) no greater than 2.5 times upper limit of normal",
        "  Renal",
        "  Creatinine normal OR",
        "  Creatinine clearance at least 60 mL/min",
        "  No clinically significant proteinuria",
        "  No significant impairment of renal function",
        "  Cardiovascular",
        "  No New York Heart Association class III or IV heart disease",
        "  No symptomatic congestive heart failure",
        "  No unstable angina pectoris",
        "  No cardiac arrhythmia",
        "  No inadequately controlled hypertension",
        "  Other",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective barrier contraception",
        "  No prior severe hypersensitivity reaction to docetaxel or drugs formulated with polysorbate 80",
        "  No other malignancy within the past 10 years except inactive nonmelanoma skin cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast, or bilateral breast cancer",
        "  No ongoing or active infection",
        "  No peripheral neuropathy greater than grade 1",
        "  No other concurrent uncontrolled medical condition that would preclude study participation",
        "  No psychiatric illness or social situation that would preclude study compliance",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy",
        "  Prior trastuzumab (Herceptin) allowed",
        "  Chemotherapy",
        "  See Disease Characteristics",
        "  No prior chemotherapy for recurrent or metastatic disease",
        "  Prior adjuvant chemotherapy allowed",
        "  Endocrine therapy",
        "  Prior hormonal therapy allowed",
        "  Radiotherapy",
        "  Not specified",
        "  Surgery",
        "  Not specified",
        "  Other",
        "  No other concurrent investigational agents"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Disease Response (Tumor Measurements)Per RECIST Criteria v. 2000",
        "  Response and progression will be evaluated in this study using the criteria by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria. Partial Response: At least a 30% decrease in the sum of the longest diameter (LD) of target lesions. Progressive Disease: At least a 20% increase in the sum of the LD of target lesions. Stable Disease: Neither sufficient shrinkage nor sufficient increase.",
        "  Time frame: after 6 course (6 months) of combination therapy",
        "Results 1: ",
        "  Arm/Group Title: Docetaxel and OSI-774",
        "  Arm/Group Description: docetaxel IV over 1 hour once weekly for 3 weeks and oral erlotinib once daily",
        "  Overall Number of Participants Analyzed: 28",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Partial response: 11",
        "  Disease progression: 14",
        "Stable disease: 3"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 28/39 (71.79%)",
        "  Anemia 1/39 (2.56%)",
        "  Leukopenia 4/39 (10.26%)",
        "  Neutropenia 4/39 (10.26%)",
        "  Chest Pain 1/39 (2.56%)",
        "  Pericarditis 1/39 (2.56%)",
        "  Sinus Tach. 1/39 (2.56%)",
        "  Sinus Tachycardia 1/39 (2.56%)",
        "  Eye tearing 1/39 (2.56%)",
        "  Diarrhea 7/39 (17.95%)",
        "  Mucositis 3/39 (7.69%)",
        "  Nausea 2/39 (5.13%)",
        "  Vomiting  [1]1/39 (2.56%)",
        "  Fatigue 6/39 (15.38%)"
    ]
}